Compare Extra Space Storage, Inc. (EXR) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Novartis AG — how do they compare? Extra Space Storage, Inc. trades at $134.65 (market cap $28.12B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 9.6× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.87%). Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 109 Days and Novartis AG for 82 Days on average.
| EXR | NVS | |
|---|---|---|
Market Cap | $28.12B | $268.57B |
Volume | 2,595,579 | 1,532,573 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $168.62 |
52-Week Low | $126.67 | $121.80 |
Typical Hold Time | 109 Days | 82 Days |
Enterprise Value | $41.84B | $309.89B |
Dividend Yield | 4.87% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $134.65, up 2.24% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Revenue grew to $3.38B in 2025, and net income margin stands at 27.79%. Analyst consensus is split evenly between Buy and Hold, with a price target of $158.33. Recent news highlights leadership transition and dividend declarations.
Outlook is balanced: solid operational performance and dividend yield support the stock, but high valuation ratios and bearish technicals pose near-term risks. Investors should weigh strong fundamentals against potential volatility from interest rate sensitivity and market sentiment shifts.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
